Hassane M. Zarour

20.4k total citations · 4 hit papers
104 papers, 8.0k citations indexed

About

Hassane M. Zarour is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Hassane M. Zarour has authored 104 papers receiving a total of 8.0k indexed citations (citations by other indexed papers that have themselves been cited), including 78 papers in Oncology, 69 papers in Immunology and 35 papers in Molecular Biology. Recurrent topics in Hassane M. Zarour's work include Cancer Immunotherapy and Biomarkers (61 papers), Immunotherapy and Immune Responses (55 papers) and CAR-T cell therapy research (42 papers). Hassane M. Zarour is often cited by papers focused on Cancer Immunotherapy and Biomarkers (61 papers), Immunotherapy and Immune Responses (55 papers) and CAR-T cell therapy research (42 papers). Hassane M. Zarour collaborates with scholars based in United States, France and Australia. Hassane M. Zarour's co-authors include John M. Kirkwood, Joë-Marc Chauvin, Julien Fourcade, Cindy Sander, Zhaojun Sun, Philippe Guillaume, Immanuel F. Luescher, Vijay K. Kuchroo, Ornella Pagliano and Mourad Benallaoua and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Investigation and The Journal of Experimental Medicine.

In The Last Decade

Hassane M. Zarour

100 papers receiving 7.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+ T cell dysfunction in melanoma patients

2010 1.0k citations Julien Fourcade, Zhaojun Sun et al. The Journal of Experimental Medicine profile →
Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001

2019 638 citations Omid Hamid, Caroline Robert et al. profile →
TIGIT and PD-1 impair tumor antigen–specific CD8+ T cells in melanoma patients

2015 608 citations Joë-Marc Chauvin, Ornella Pagliano et al. profile →
TIGIT in cancer immunotherapy

2020 555 citations Joë-Marc Chauvin, Hassane M. Zarour Journal for ImmunoTherapy of Cancer profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Hassane M. Zarour United States	41	5.6k	5.2k	1.9k	688	414	104	8.0k
Hideto Tamura Japan	25	5.4k 1.0×	5.0k 1.0×	1.2k 0.6×	824 1.2×	330 0.8×	88	8.0k
Laura Carter United States	23	4.1k 0.7×	5.2k 1.0×	1.1k 0.6×	644 0.9×	502 1.2×	45	7.7k
Michael Yellin United States	38	4.7k 0.8×	5.2k 1.0×	1.6k 0.9×	543 0.8×	551 1.3×	112	8.2k
Loise M. Francisco United States	16	3.3k 0.6×	5.8k 1.1×	1.4k 0.7×	532 0.8×	523 1.3×	19	8.0k
Yuanyuan Zha United States	22	4.5k 0.8×	3.2k 0.6×	2.5k 1.3×	826 1.2×	295 0.7×	67	6.8k
Kristen E. Pauken United States	27	4.5k 0.8×	5.4k 1.0×	1.4k 0.7×	622 0.9×	662 1.6×	39	8.0k
Bryan Irving United States	20	4.1k 0.7×	5.5k 1.0×	1.7k 0.9×	469 0.7×	270 0.7×	44	7.8k
Clive R. Wood United States	21	4.4k 0.8×	5.2k 1.0×	1.8k 1.0×	695 1.0×	440 1.1×	35	8.4k
Yoshiko Iwai Japan	21	7.1k 1.3×	6.8k 1.3×	1.8k 0.9×	1.2k 1.7×	609 1.5×	30	10.7k
Thorbald van Hall Netherlands	47	4.1k 0.7×	6.1k 1.2×	2.5k 1.3×	421 0.6×	541 1.3×	127	8.1k

Countries citing papers authored by Hassane M. Zarour

Since Specialization

Citations

This map shows the geographic impact of Hassane M. Zarour's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hassane M. Zarour with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hassane M. Zarour more than expected).

Fields of papers citing papers by Hassane M. Zarour

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hassane M. Zarour. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hassane M. Zarour. The network helps show where Hassane M. Zarour may publish in the future.

Co-authorship network of co-authors of Hassane M. Zarour

This figure shows the co-authorship network connecting the top 25 collaborators of Hassane M. Zarour. A scholar is included among the top collaborators of Hassane M. Zarour based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hassane M. Zarour. Hassane M. Zarour is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Karunamurthy, Arivarasan, Douglas J. Hartman, Hong Wang, et al.. (2024). Automated Quantitative CD8+ Tumor-Infiltrating Lymphocytes and Tumor Mutation Burden as Independent Biomarkers in Melanoma Patients Receiving Front-Line Anti-PD-1 Immunotherapy. The Oncologist. 29(7). 619–628. 4 indexed citations

Zang, Yan, Hong Wang, Cindy Sander, et al.. (2024). A phase II trial of nivolumab plus axitinib in patients with anti-PD1 refractory advanced melanoma.. Journal of Clinical Oncology. 42(16_suppl). TPS9600–TPS9600. 1 indexed citations

Amatore, F., Shaum Sridharan, Arivarasan Karunamurthy, et al.. (2024). Pathologic response rates to neoadjuvant pembrolizumab in locally advanced (LA) resectable cutaneous squamous cell carcinoma (cSCC).. Journal of Clinical Oncology. 42(16_suppl). 9591–9591. 5 indexed citations

Burns, Timothy F., Hong Wang, Liza C. Villaruz, et al.. (2024). Phase I/II trial of healthy donor fecal microbiota transplant (hdFMT) in PD-1 relapsed/refractory (R/R) non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 42(16_suppl). TPS8648–TPS8648. 4 indexed citations

Augustin, Ryan C., Sarah Newman, Marion Joy, et al.. (2023). Identification of tumor-intrinsic drivers of immune exclusion in acral melanoma. Journal for ImmunoTherapy of Cancer. 11(10). e007567–e007567. 8 indexed citations

Augustin, Ryan C., Marion Joy, Peter C. Lucas, et al.. (2023). 888 Identification of tumor-intrinsic drivers of immune exclusion in acral melanoma. SHILAP Revista de lepidopterología. A989–A989. 1 indexed citations

Davar, Diwakar & Hassane M. Zarour. (2022). Facts and Hopes for Gut Microbiota Interventions in Cancer Immunotherapy. Clinical Cancer Research. 28(20). 4370–4384. 32 indexed citations

Chauvin, Joë-Marc, Mignane Ka, Ornella Pagliano, et al.. (2020). IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma. Clinical Cancer Research. 26(20). 5520–5533. 114 indexed citations

Shao, Lulu, Weizhou Hou, Nicole E. Scharping, et al.. (2019). IRF1 Inhibits Antitumor Immunity through the Upregulation of PD-L1 in the Tumor Cell. Cancer Immunology Research. 7(8). 1258–1266. 52 indexed citations

10.

Ascierto, Paolo A., James Brugarolas, Luigi Buonaguro, et al.. (2018). Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge (29-30 November, 2017, Naples, Italy). Journal for ImmunoTherapy of Cancer. 6(1). 69–69. 9 indexed citations

11.

Robert, Caroline, Antoni Ribas, Omid Hamid, et al.. (2017). Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma. Journal of Clinical Oncology. 36(17). 1668–1674. 336 indexed citations

12.

Sun, Zhaojun, Julien Fourcade, Ornella Pagliano, et al.. (2015). IL10 and PD-1 Cooperate to Limit the Activity of Tumor-Specific CD8+ T Cells. Cancer Research. 75(8). 1635–1644. 141 indexed citations

13.

Fourcade, Julien, Zhaojun Sun, Ornella Pagliano, et al.. (2013). PD-1 and Tim-3 Regulate the Expansion of Tumor Antigen–Specific CD8+ T Cells Induced by Melanoma Vaccines. Cancer Research. 74(4). 1045–1055. 175 indexed citations

14.

Kirkwood, John M., Lisa H. Butterfield, Ahmad A. Tarhini, et al.. (2012). Immunotherapy of cancer in 2012. CA A Cancer Journal for Clinicians. 62(5). 309–335. 345 indexed citations

15.

Zarour, Hassane M. & Soldano Ferrone. (2011). Cancer immunotherapy: Progress and challenges in the clinical setting. European Journal of Immunology. 41(6). 1510–1515. 24 indexed citations

16.

Fourcade, Julien, Zhaojun Sun, Ornella Pagliano, et al.. (2011). CD8+ T Cells Specific for Tumor Antigens Can Be Rendered Dysfunctional by the Tumor Microenvironment through Upregulation of the Inhibitory Receptors BTLA and PD-1. Cancer Research. 72(4). 887–896. 291 indexed citations

17.

Fourcade, Julien, Zhaojun Sun, Mourad Benallaoua, et al.. (2010). Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+ T cell dysfunction in melanoma patients. The Journal of Experimental Medicine. 207(10). 2175–2186. 1032 indexed citations breakdown →

18.

Janjic, Bratislav, Xiaofei Wang, Julien Fourcade, et al.. (2006). Spontaneous CD4+ T Cell Responses against TRAG-3 in Patients with Melanoma and Breast Cancers. The Journal of Immunology. 177(4). 2717–2727. 15 indexed citations

19.

Mandić, Maja, Florence Castelli, Bratislav Janjic, et al.. (2005). One NY-ESO-1-Derived Epitope That Promiscuously Binds to Multiple HLA-DR and HLA-DP4 Molecules and Stimulates Autologous CD4+ T Cells from Patients with NY-ESO-1-Expressing Melanoma. The Journal of Immunology. 174(3). 1751–1759. 57 indexed citations

20.

Grob, Jean‐Jacques, et al.. (1995). Cost-Effectiveness of Surveillance of Stage I Melanoma. Dermatology. 191(3). 199–203. 66 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact